New Lipid Lowering Therapies for Cardiovascular and Metabolic Diseases: Lessons from the Past and Future Challenges
Material type:
ArticleLanguage: English Publication details: MDPI - Multidisciplinary Digital Publishing Institute 2019Description: 1 electronic resource (116 p.)ISBN: - books978-3-03921-677-2
- 9783039216772
- 9783039216765
- apolipoprotein
- lipids
- risk stratification
- proprotein convertase subtilisin-kexin type 9 (PCSK9)
- vaspin
- sphingolipids
- PCSK9
- ceramides
- atrial fibrillation
- circular RNA
- STEMI
- cholesterol
- lipoproteins
- cardiovascular disease (CVD)
- coronary artery bypass grafting
- atherosclerosis
- statin
- LDL subfractions
- acute kidney injury
- dyslipidemia
- gene expression
- NSTEMI
- NAFLD
- hyperlipidemia
- nonstatin
- cholesteryl ester transfer protein
- low-density lipoprotein cholesterol
- anacetrapib
- HDL
- acute coronary syndrome
- miRNA
- cardiovascular risk
- pleiotropic actions
- genetic
- ABCA1
- sdLDL
- cardiovascular disease
- proprotein convertase subtilisin/kexin type 9
- inclisiran
- reverse cholesterol transport
- sterol
- small interfering RNA (siRNA)
- RNA-binding proteins
- cardiovascular diseases
- NASH
- low-density lipoprotein-cholesterol (LDL-C)
- stroke
- nutrigenetics
- type 2 diabetes
- statins
- sphingomyelin
- hepatic fibrosis
- diabetes
| Item type | Home library | Collection | Call number | Materials specified | Status | Date due | Barcode | |
|---|---|---|---|---|---|---|---|---|
Electronic-Books
|
OPJGU Sonepat- Campus | E-Books Open Access | Available |
Open Access star Unrestricted online access
This book illustrates some of the most recent research efforts that have been made in lowering plasma cholesterol levels in patients with CVD. Selected articles aimed to illuminate advances and urgent challenges in the management of CVD, including disease management using statin-combined therapeutic strategies.
Creative Commons https://creativecommons.org/licenses/by-nc-nd/4.0/ cc https://creativecommons.org/licenses/by-nc-nd/4.0/
English
There are no comments on this title.